Düşük Serum Serulapozmin Aktivitesi Aterosklerozun Göstergesi Olabilir: Kesitsel Bir Çalışma

Yıl 2015, Cilt: 12 Sayı: 2, 200 - 205, 30.08.2015

Hatice Sezen Emin Savik , Ahmet Kaymaz Musluhittin Emre Erkus , İbrahim Halil Altiparmak , Abdullah Nurdağ Abdusselam İlter Nurten Aksoy

Öz

Giriş
Daha önceki çalışmalarda serum seruloplazmin (Cp) seviyesi ile aterosklerotik kalp hastalığı arasında ilişki
bulunmuş ancak bu ilişkinin iskemi mi yoksa ateroskleroz mu kaynaklı olduğu araştırılmamıştır. Bu
çalışmanın amacı Cp aktivitesinin koroner ateroskleroz ve iskemi ile ilişkisini ayrı ayrı değerlendirerek
hangisine bağlı olduğunu araştırmaktır.
Materyal ve Metod
Koroner anjiyografi için alınan 90 hasta çalışmaya dâhil edildi. Hastalar koroner arter hastalığı (KAH): En az
1 ana koroner arterinde % 70 ve üzerinde darlık olan ve iskemi varlığı kanıtlanmış hastalar; nonkritik koroner
darlık (NOK): en az 1 ana koroner arterinde % 70'in altında darlığı olan ve açık iskemisi olmayan, normal
koroner arter (NKA): koronerlerinde herhangi bir aterosklerotik hastalık tespit edilemeyen ardışık 30 hasta
şeklinde gruplandı. Çalışmaya alınan tüm hastalardan enzimatik olarak ticari kitlerle lipid profili ve Erel
Metodu serum Cp aktivitesi ile ölçüldü.
Sonuçlar
Gruplar yaş cinsiyet, beden-kitle indeksi ve lipit profili yönünden benzerdi (p>0,05). Serum Cp aktivitesi
3 grup arasında anlamlı düzeyde farklı idi (p<0,05) ve hasta gruplarında NKA grubuna göre düşüktü. Alt
grup analizinde bu farkın NKA grubuyla diğer gruplar arasında olduğu görüldü. Pearson korelasyon
analizinde serum Cp aktivitesi ile total kolesterol ve düşük dansiteli lipoprotein kolesterol ile negatif ve
yüksek dansiteli lipoprotein kolesterol ile pozitif ilişkili olduğu görüldü. Linier regresyon analizinde bu
parametrelerden serum Cp aktivitesini sadece serum yüksek dansiteli lipoprotein kolesterol seviyesinin
etkilediği görüldü.Tartışma
Sonuç olarak, koroner ateroskleroz olan hastalarda serum Cp aktivitesi yüksek oksidatif stresi gösterecek
şekilde düşük olarak ölçüldü. İskemi olması ya da olmamasının sonucu etkilemediği gözlendi.

Anahtar Kelimeler

Seruloplazmin, Ateroskleroz, Oksidatif Stres

Low Serum Ceruloplasmin Activity May Be An Indicator Of Atherosclerosis: A Cross Sectional Study

Öz

Background
In previous studies, serum ceruloplasmin (Cp) level have been shown to be correlated with atherosclerotic
heart disease. But it has not been investigated which result from ischemia or atherosclerosis. The aim of this
study, serum Cp activity assess in coronary atherosclerosis and ischemia and investigate to which it is
connected.
Methods
90 patients taken for coronary angiography were included in the study. Patients divided three groups such as
coronary artery disease (CAD): at least one main coronary artery stenosis exceeding 70% and patients with
proven ischemia presence; noncritical coronary artery stenosis (NOC): at least one main coronary artery stenosis
less than 70% and no obvious ischemia, normal coronary artery (NKA): 30 consecutive patients with
normal coronary artery. Lipid profiles of all patients were measured. And serum Cp activity was measured by
Erel's method.
Results
Tree groups were similar in terms of age, gender, BMI and lipid profile (p> 0.05). Serum Cp activity was
significantly different among groups (p <0.05). CP activity was significantly lower in the patient group
compared to the NOC group. In the subgroup analysis this difference was observed among NKA group and
other groups. Pearson correlation analysis showed that serum Cp activity is the negative with total
cholesterol and low density lipoprotein cholesterol, positively correlated with high density lipoprotein
cholesterol (HDLK). Linier regression analysis showed that only HDLK effect serum Cp activity from these
parameters independently.
Conclusions
As a result, in patients with atherosclerosis, serum Cp activity was lower than in patients with normal
coronary arteries. The presence of ischemia did not affect the result.

Anahtar Kelimeler

Ceruloplasmin, Atherosclerosis, Oxidative Stress

Kaynakça

• 1.WHO Fact sheet N°310, Updated May 2014, http://www.who.int/mediacentre/ factsheets/fs310/en/ 2. Widimsky P, Wijns W, Fajadet J, de Belder M, Knot J, Aaberge L, et al. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J 2010;31:943-57. 1. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death Circulation 2006;114:385- 484. 2. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129: 1-45. 3.Hellman NE, Gitlin JD. Ceruloplasmin metabolism and function. Annu Rev Nutr 2002;22:439-58. 4.Hellman NE, Kono S, Mancini GM, Hoogeboom AJ, De Jong GJ, Gitlin JD. Mechanisms of copper incorporation into human ceruloplasmin. J Biol Chem 2002;277(48):46632-8. 5.Correale M, Totaro A, Abruzzese S, Di Biase M, Brunetti ND. Acute phase proteins in acute coronary syndrome: an up-to-date. Cardiovasc Hematol Agents Med Chem 2012;10(4):352-61. 6.Brunetti ND, Pellegrino PL, Correale M, De Gennaro L, Cuculo A, Di Biase M. Acute phase proteins and systolic dysfunction in subjects with acute myocardial infarction. J Thromb Thrombolysis 2008;26(3):196- 202. 7.Kaur K, Bedi G, Kaur M, Vij A, Kaur I. Lipid peroxidation and the levels of antioxidant enzymes in coronary artery disease. Indian J Clin Biochem 2008;23(1):33- 7. 8.Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low- density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502. 9.Erel O. Automated measurement of serum ferroxidase activity. Clin Chem 1998;44:2313-9. 10.Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Biochem 2004;37:112-9. 13.Widimsky P, Wijns W, Fajadet J, de Belder M, Knot J, Aaberge L, et al. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J 2010;31:943-57. 14.Dendramis G, Paleologo C, Lo Presti A, Piraino D, Lo Greco V, Grassedonio E, et al. Coronary artery ectasia: etiopathogenesis, diagnosis and treatment. G Ital Cardiol (Rome)2014;15(3):161-9. 15. Lenz T. [Current management ofrenal artery stenosis]. Internist (Berl) 2013;54(12):1443-9. 16. Tanweer O, Wilson TA, Metaxa E, Riina HA, Meng H. A comparative review of the hemodynamics and pathogenesis of cerebral and abdominal aortic aneurysms: lessons to learn from each other. J Cerebrovasc Endovasc Neurosurg 2014;16(4):335-49. 17. Manea A, Simionescu M. Nox enzymes and oxidative stress in atherosclerosis. Front Biosci 2012;4:651-70. 18. Peluso I, Morabito G, Urban L, Ioannone F, Serafini M. Oxidative stress in atherosclerosis development: the central role of LDL and oxidative burst. Endocr Metab Immune Disord Drug Targets 2012;12(4):351-60. 19.Göçmen AY, Sahin E, Semiz E, Gümuşlü S. Is elevated serum ceruloplasmin level associated with increased risk of coronary artery disease? Can J Cardiol 2008;24(3):209-12. 20. Grammer TB, Kleber ME, Silbernagel G, Pilz S, Scharnagl H, Lerchbaum E, et al. Copper, ceruloplasmin, and long-term cardiovascular and total mortality (the Ludwigshafen Risk and Cardiovascular Health Study). Free Radic Res 2014;48(6):706-15. 21. Ziakas A, Gavrilidis S, Souliou E, Giannoglou G, Stiliadis I, Karvounis H, et al. Ceruloplasmin is a better predictor of the long-term prognosis compared with Harran Üniversitesi Tıp Fakültesi Dergisi (Journal of Harran University Medical Faculty) Cilt 12. Sayı 2, 2015fibrinogen, CRP, and IL-6 in patients with severe unstable angina. Angiology 2009;60(1):50-9. 16. Brunetti ND, Pellegrino PL, Correale M, De Gennaro L, Cuculo A, Di Biase M. Acute phase proteins and systolic dysfunction in subjects with acute myocardial infarction. J Thromb Thrombolysis 2008;26(3):196-202. 17. Brunetti ND, Correale M, Pellegrino PL, Cuculo A, Biase MD. Acute phase proteins in patients with acute coronary syndrome: Correlations with diagnosis,clinical features, and angiographic findings. Eur J Intern Med 2007;18(2):109-17. 18. Lamb DJ, Leake DS. Acidic pH enables caeruloplasmin to catalyse the modification of low density lipoprotein. FEBS Lett 1994;338(2):122-26 19. Healy J, Tipton K. Ceruloplasmin and what it might do. J Neural Transm 2007;114(6):777-81. 20. Jayakumari N, Ambikakumari V, Balakrishnan KG, Iyer KS. Antioxidant status in relation to free radical production during stable and unstable anginal syndromes. Atherosclerosis 1992;94:183-90. 21. Biasucci LM, Santamaria M, Liuzzo G. Inflammation, atherosclerosis and acute coronary syndromes. Minerva Cardioangiol 2002;50(5):475-86. 22. Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler. Thromb. Vasc. Biol 2007;27(1):161- 7. 23.Mackness M, Mackness B. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important? Free Radic Biol Med 2004;37(9):1317-23.